CAJ | 학술논문

目的探讨阿霉素、博莱霉素、长春新碱、氮烯咪胺(ABVD)第1、8天用药方案治疗初治霍奇金淋巴瘤(HL)的疗效.方法将我院2005年10月-2006年10月收治的Ⅱ～Ⅳ期初治HL62例患者,采用随机分组的方法将患者分为A、B两组,每组均为31例,A组采用ABVD第1、8天用药方案进行化疗6～8周期,B组采用ABVD第1、15天用药方案进行化疗6～8周期,两组患者化疗结束后均南同一位放疗科医生根据具体情况给予放疗,制定放疗方案不受A、B分组的影响.结果 A组化疗结束后完全缓解(CR)率90.3%(28/31),1年无病生存(DFS)率87.1%(27/31),2年DFS80.0%(20/25).B组化疗结束后CR 83.9%(26/31),1年DFS 80.6%(25/31),2年DFS 72.0%(18/25).A、B两组CR率、1年DFS率、2年DFS率比较,差异均无统计学意义(P>0.05).治疗相关的毒副反应,心肌缺血、Ⅲ～Ⅳ度肝功能损害、重度骨髓抑制等比较,差异无统计学意义(p>0.05).A组每例患者从化疗开始到化疗结束的平均时间为159 d,B组为228 d,A组较B组平均每人缩短69 d.结论采用ABVD第1、8天用药方案治疗初治Ⅱ～Ⅳ期HL与第1、15天用药方案治疗CR率、1年DFS率、2年DFS率比较均相似,但A组有优于B组的趋势,治疗相关的毒副反应也相似,但在治疗时间上A组显著缩短.
목적 탐토아매소、박래매소、장춘신감、담희미알(ABVD)제1、8천용약방안치료초치곽기금림파류(HL)적료효.방법 장아원2005년10월-2006년10월수치적Ⅱ～Ⅳ기초치HL62례환자,채용수궤분조적방법장환자분위A、B량조,매조균위31례,A조채용ABVD제1、8천용약방안진행화료6～8주기,B조채용ABVD제1、15천용약방안진행화료6～8주기,량조환자화료결속후균남동일위방료과의생근거구체정황급여방료,제정방료방안불수A、B분조적영향.결과 A조화료결속후완전완해(CR)솔90.3%(28/31),1년무병생존(DFS)솔87.1%(27/31),2년DFS80.0%(20/25).B조화료결속후CR 83.9%(26/31),1년DFS 80.6%(25/31),2년DFS 72.0%(18/25).A、B량조CR솔、1년DFS솔、2년DFS솔비교,차이균무통계학의의(P>0.05).치료상관적독부반응,심기결혈、Ⅲ～Ⅳ도간공능손해、중도골수억제등비교,차이무통계학의의(p>0.05).A조매례환자종화료개시도화료결속적평균시간위159 d,B조위228 d,A조교B조평균매인축단69 d.결론 채용ABVD제1、8천용약방안치료초치Ⅱ～Ⅳ기HL여제1、15천용약방안치료CR솔、1년DFS솔、2년DFS솔비교균상사,단A조유우우B조적추세,치료상관적독부반응야상사,단재치료시간상A조현저축단.
Objective To explore the effect of adriamycin, bleomyein, vincristine and dacarbazinum (ABVD) chemotherapy scheme executed at day I and day 8 for primary Hodgkin's lymphomas (HL). Methods 62 patients with primary HL in stages Ⅱ-Ⅳ treated in our department from October 2005 to October 2006 were divided into group A and B at random with 31 patients in each group. The patients in group A received ABVD chemotherapy scheme executed at day 1 and day 8 for 6-8 cycles. The patients in group B received ABVD chemotherapy scheme executed at day 1 and day 15 for 6-8 cycles. The patients of the groups received radiotherapy by the same doctor after chemotherapy according to the patients condition and the radiotherapy regimens were not affected by the grouping. Results The complete remission rate (CR)in group A after chemotherapy was 90. 3% (28/31);the one-year and two-year disease free survival (DFS) rates were 87. 1% (27/31) and 80.0% (20/25)respectively. The CR rate in group B after chemotherapy was 83.9% (26/31);the one-year and two-year DFS rates were 80. 6% (25/31)and 72. 0% (18/25) respectively. The discrepancy of CR rates and the one-year and two-year DFS rates between the two groups was not significant (P>0.05). The incidences of therapeutic side effecte such as myocardial iscnemia grade Ⅲ-Ⅳ liver function impair-ment,pulmonary fibrosis and serious marrow inhibition between the two groups were not significant too (P > 0.05). Average chemotherapy period for the patients in group A was 159 days; it was 69 days shorter than that in group B. Conclusion The CR rate,1-year DFS rate and 2-year DFS rate of ABVD chemotherapy scheme executed at day 1 and 8 are similar to those of ABVD chemotherapy scheme executed at day Ⅰ and 15 for primary HL in stages Ⅱ-Ⅳ. The side-effects of chemoterapy between group A and B are similar too. The chemotherapy period in group A is shortened significantly.